The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected to neutralize omicron subvariants BQ.1 and BQ.1.1. While bebtelovimab remains authorized in all U.S. regions until further notice, prescribers should monitor the Centers for Disease Control and Prevention’s regional variant frequency data and refer to the provider fact sheet for details regarding resistance against SARS-CoV-2 variants in their area, FDA said

In other news, FDA yesterday warned health care professionals that naloxone may not be able to reverse the effects of xylazine in fentanyl, heroin and other illicit drug overdoses. FDA is aware of increasing reports of serious side effects from individuals exposed to fentanyl, heroin and other illicit drugs contaminated with xylazine, a sedative and pain reliever that FDA has approved for use in animals.

Related News Articles

Headline
The AHA is offering a new set of social messages and assets for February to encourage the public to get vaccinated and boosted against COVID-19. The new…
Headline
A Food and Drug Administration advisory committee unanimously voted today to recommend harmonizing the composition of all COVID-19 vaccine primary series and…
Headline
In a study released today by the Centers for Disease Control and Prevention, a single bivalent COVID-19 vaccine booster provided additional protection against…
Headline
A Food and Drug Administration advisory committee is scheduled to vote Thursday on whether to simplify current COVID-19 vaccine use so that all primary series…
Headline
Evusheld may not prevent COVID-19 in immunocompromised individuals exposed to the XBB.1.5 omicron subvariant, because the treatment has failed to neutralize…
Headline
In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported…